

Press release

MEDIAN Technologies and Microsoft sign collaborative agreement to develop new cancer detection, diagnosis and monitoring methods using Big Data analytics

SOPHIA ANTIPOLIS, France and ISSY-LES-MOULINEAUX, France – June 22, 2016 – MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology, and Microsoft announced today a joint global initiative in the rapidly growing Precision Medicine market to develop new cancer detection, diagnosis and monitoring methods using Big Data analytics. As part of the initiative, MEDIAN Technologies will collaborate with Microsoft to install its groundbreaking imaging biomarker phenotyping system (IBIOPSY™) on the Microsoft Azure cloud computing platform. On Azure, IBIOPSY™ will provide capabilities for processing and analyzing medical images, extracting biomarkers of disease in real time for cancer diagnosis and treatment purposes.

“Precision Medicine is about to revolutionize how diagnostic and biological data is used to pinpoint and deliver care that is preventive, targeted and effective” said Fredrik Brag Chief Executive Officer at MEDIAN Technologies. *“Extracting biomarkers of disease from medical images is at the core of the Precision Medicine effort. Big Data computing and analytics will allow efficient processing and analysis of imaging biomarkers which is essential for early detection of cancer and monitoring of new targeted cancer treatments. Our collaboration with Microsoft will allow us to deliver these solutions into routine clinical practice on a global scale on the Azure Cloud Computing platform.”*

“Microsoft Innovation teams are committed to providing their technical expertise to health professionals who use medical images in their daily routine. We are proud to collaborate with MEDIAN on the IBIOPSY™ project and to bring innovative technologies at the service of cancer research”, said Bernard Ourghanlian, Chief Technology & Security Officer at Microsoft France. *“Indeed, we are, more than ever committed to addressing the biggest challenges in cancer detection, diagnosis and monitoring, by offering access to the latest and most innovative technologies. By taking advantage of the powerful Microsoft Azure cloud platform, IBIOPSY™ will provide faster imaging and health data analysis and will accelerate the discovery and delivery of new biomarkers for cancer diagnosis and treatment monitoring.”*

IBIOPSY™ will eventually be made available to medical facilities and physicians in the US, Europe, and Asia to meet the image processing and data analytics needs created by the next generation of personalized cancer therapies and the explosive growth in medical imaging data. MEDIAN Technologies and Microsoft will work together to help medical centers take advantage of the Azure capabilities. Also MEDIAN Technologies and Microsoft collaboration will focus on the development of novel predictive analytics methods based on machine learning and encryption capabilities that will be available on Azure.

About Microsoft

Founded in 1975, Microsoft (Nasdaq “MSFT”) is the worldwide leader in software, services and solutions that help people and businesses realize their full potential through digital technologies. Established in 1983, Microsoft France employs 1,500 people and has been run by Alain Crozier since July 2012.



About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world’s largest CRO (Contract

Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. ISIN: FR0011049824– ticker: ALMDT The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechologies.com

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”



Contact Microsoft France

Juliette Villeroy – 01 58 65 10 77 – jvilleroy@hopscotch.fr

Amandine Bonnefis – 01 58 65 10 06 – abonnefis@hopscotch.fr

Contacts MEDIAN Technologies

MEDIAN Technologies Fredrik Brag, CEO +33 4 92 90 65 82 fredrik.brag@mediantechnologies.com	Press: ALIZE RP Caroline Carmagnol / Wendy Rigal + 33 1 44 54 36 66 median@alizerp.com	Investors : ACTIFIN Ghislaine Gasparetto +33 1 56 88 11 11 ggasparetto@actifin.fr
--	--	---